Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new treatment for myeloma patients who still have some disease remaining after induction therapy. The goal is to see if this new treatment can help these patients achieve a complete response.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have high-risk multiple myeloma and finished a treatment with at least 2 drugs before a stem cell transplant.I am 18 years old or older.I do not have any active and uncontrolled infections.
- Group 1: Descartes 08
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How can people sign up for this opportunity?
"That is correct. The information on clinicaltrials.gov indicates that the trial, which was first advertised on December 1st 2021, is still recruiting patients. They need 30 more participants and have 2 sites where people can enroll."
What is the Descartes 08 drug's official standing with the FDA?
"Because a Phase 2 trial only provides evidence of safety and not efficacy, our team has given Descartes 08 a score of 2."
How many individuals are included in this experiment?
"Yes, this information can be found on clinicaltrials.gov. The trial was posted on December 1st 2021 and updated April 4th 2022. They are looking for 30 participants total at 2 sites."
Share this study with friends
Copy Link
Messenger